Ray Dalio's hedge fund might be dropped by a California retirement fund after years of disappointing returns, report says
Ray Dalio's Bridgewater might be dropped by a California employee pensionfund, Bloomberg reported.
- The Orange County Employees Retirement System has invested in Dalio's fund since 2005.
- The pension's CIO has recommended putting Dalio's fund on its watch list, according to the report.
The Orange County Employees Retirement System, a $21 billion pension, has invested in Dalio's
The strategy has outperformed the pension's target only once in the last five years and has lagged when it came to a seven- and 10-year time frame, Bloomberg reported.
Pure Alpha, according to the memo, represents almost 10% of the pension's risk mitigation asset class. The pension's CIO, Molly Murphy, has recommended putting
However, being on a watch list doesn't mean the fund will definitely be dropped. Many hedge funds in recent years have struggled, Meketa consultants said in the memo, pointing to Bridgewater's attempts to improve performance.
Bridgewater, which Dalio founded in 1975, oversees around $175 million for the pension, a tiny percentage of the over $105 billion it manages in its hedge funds.
In 2020, Dalio's Bridgewater lost $12.1 billion for investors, a year when the world's top 20 hedge funds reaped their best returns in a decade. Still, the billionaire was still considered the best-performing hedge fund manager of all time, according to LCH Investments.
- A college is removing its vending machines after a student discovered they were using facial-recognition technology
- 11 states pay more in federal taxes than they get back - here's how every state fares
- Steve Jobs once said the best managers are 'individual contributors' who aren't interested in managing people
- Fuel your morning: Wholesome South Indian breakfast ideas for health
- Vodafone Idea shares tumble 14%, mcap erodes ₹10,806.7 cr
- National parties declare income of ₹3,077 cr in 2022-23; BJP has highest share
- Human trials may reveal efficacy of new Rs 100 cancer pill: Docs
- Multiplexes' revenue growth to dip to 15% in FY25 as OTTs crimp profit margins